These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 15504890)

  • 1. Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta-lactamases.
    Bowker KE; Noel AR; Walsh TR; Rogers CA; MacGowan AP
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4482-4. PubMed ID: 15504890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel extended-spectrum beta-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance.
    Stürenburg E; Kühn A; Mack D; Laufs R
    J Antimicrob Chemother; 2004 Aug; 54(2):406-9. PubMed ID: 15201232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefotaxime and ceftazidime-resistant Escherichia coli isolate producing TEM-15 beta-lactamase from a Tunisian hospital.
    Chouchani C; Ben-Achour N; M'charek A; Belhadj O
    C R Biol; 2007 Aug; 330(8):565-70. PubMed ID: 17637436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of the evolution of ceftazidime resistance in extended-spectrum beta-lactamase CTX-M-9.
    Delmas J; Robin F; Carvalho F; Mongaret C; Bonnet R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):731-8. PubMed ID: 16436733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
    Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-antibiotic and post-beta-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum beta-lactamase-producing Gram-negative bacteria.
    Lavigne JP; Bonnet R; Michaux-Charachon S; Jourdan J; Caillon J; Sotto A
    J Antimicrob Chemother; 2004 Apr; 53(4):616-9. PubMed ID: 14985275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
    Weston GS; Blázquez J; Baquero F; Shoichet BK
    J Med Chem; 1998 Nov; 41(23):4577-86. PubMed ID: 9804697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of high-level ceftazidime resistance via single-base substitutions of blaCTX-M-3 in hyper-mutable Escherichia coli.
    Karisik E; Ellington MJ; Pike R; Livermore DM; Woodford N
    Clin Microbiol Infect; 2006 Aug; 12(8):803-6. PubMed ID: 16842579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-function studies of arginine at position 276 in CTX-M beta-lactamases.
    Pérez-Llarena FJ; Cartelle M; Mallo S; Beceiro A; Pérez A; Villanueva R; Romero A; Bonnet R; Bou G
    J Antimicrob Chemother; 2008 Apr; 61(4):792-7. PubMed ID: 18281307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel SHV-derived extended-spectrum beta-lactamase, SHV-57, that confers resistance to ceftazidime but not cefazolin.
    Ma L; Alba J; Chang FY; Ishiguro M; Yamaguchi K; Siu LK; Ishii Y
    Antimicrob Agents Chemother; 2005 Feb; 49(2):600-5. PubMed ID: 15673739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMT-type beta-lactamase TEM-125, an emerging problem for extended-spectrum beta-lactamase detection.
    Robin F; Delmas J; Archambaud M; Schweitzer C; Chanal C; Bonnet R
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2403-8. PubMed ID: 16801418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
    Robin F; Delmas J; Brebion A; Dubois D; Constantin JM; Bonnet R
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4181-3. PubMed ID: 17709463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
    Livermore DM; Mushtaq S; Nguyen T; Warner M
    Int J Antimicrob Agents; 2011 May; 37(5):405-9. PubMed ID: 21276715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of CTX-M-12 extended-spectrum beta-lactamase-producing Escherichia coli in Korea.
    Bae IK; Lee YN; Hwang HY; Jeong SH; Lee SJ; Kwak HS; Song W; Kim HJ; Youn H
    J Antimicrob Chemother; 2006 Dec; 58(6):1257-9. PubMed ID: 17003059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of penam sulfones as inhibitors of beta-lactamases.
    Phillips OA; Reddy AV; Setti EL; Spevak P; Czajkowski DP; Atwal H; Salama S; Micetich RG; Maiti SN
    Bioorg Med Chem; 2005 Apr; 13(8):2847-58. PubMed ID: 15781395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to the third-generation cephalosporin ceftazidime by a deacylation-deficient mutant of the TEM β-lactamase by the uncommon covalent-trapping mechanism.
    Antunes NT; Frase H; Toth M; Mobashery S; Vakulenko SB
    Biochemistry; 2011 Jul; 50(29):6387-95. PubMed ID: 21696166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor-sensitive AmpC beta-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins.
    Doi Y; Wachino J; Ishiguro M; Kurokawa H; Yamane K; Shibata N; Shibayama K; Yokoyama K; Kato H; Yagi T; Arakawa Y
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2652-8. PubMed ID: 15215122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
    Lewis JS; Herrera M; Wickes B; Patterson JE; Jorgensen JH
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.